Under Nasdaq Listing Rule 5810(c)(3)(C), CalciMedica has a grace period of 180 calendar days, until September 9, 2026, to regain compliance with the MVLS Requirement. The company can achieve this by either maintaining stockholders' equity of at least $2.5 million, achieving a market value of listed securities of at least $35 million, or reporting net income from continuing operations of $500,000 in the most recent fiscal year or in two of the last three fiscal years.
To regain compliance with the minimum bid price requirement, the company's stock must close at or above $1.00 per share for a minimum of 10 consecutive business days during the 180-day compliance period, which ends on September 14, 2026. If CalciMedica fails to meet these requirements, it may face delisting from the Nasdaq Capital Market.
The notifications of noncompliance do not immediately affect the trading of CalciMedica's common stock, which continues to trade under the symbol 'CALC'. The company plans to actively monitor its compliance status and is considering options to regain compliance, including a potential reverse stock split. However, there is no assurance that the company will be able to meet the Nasdaq listing requirements in the future.
